Clinical Guidelines Archives - Page 19 of 41

News
ID consult for Candida bloodstream infections can reduce mortality risk
January 12, 2020
More patients survived Candida bloodstream infections when they had ID consultations.
News
Experts call to revise the Uniform Determination of Death Act
January 3, 2020
A neurologist and her colleagues propose changes with the goal of clarifying and harmonizing procedures for determining death by neurologic criteria.
News
Improving sepsis-related outcomes
December 12, 2019
A dedicated quality improvement project shows results.
Opinion
Guideline: Diagnosis and treatment of adults with community-acquired pneumonia
November 22, 2019
The practice guideline was jointly written by an ad hoc committee of the American Thoracic Society and Infectious Diseases Society of America.
News
Geriatric IBD hospitalization carries steep inpatient mortality
November 21, 2019
SAN ANTONIO – A major unmet need exists for better guideline-directed management of geriatric patients hospitalized for IBD.
News
Better time data from in-hospital resuscitations
November 11, 2019
Acquiring accurate time-interval data is “the key to future high-quality research.”
News
Previously healthy patients hospitalized for sepsis show increased mortality
November 5, 2019
WASHINGTON – U.S. patients hospitalized with community-acquired sepsis had higher mortality when they had no other comorbidities.
News
Vitamin C–based regimens in sepsis plausible, need more data, expert says
October 22, 2019
NEW ORLEANS – Results from the randomized, phase 3 VICTAS study, anticipated in the coming months, may shed light on the clinical role of this adjunctive strategy.
News
Early palliative care consult decreases in-hospital mortality
October 21, 2019
NEW ORLEANS – More discharges to hospice, and more health care surrogates chosen, when palliative care consultation occurs within 24 hours of ICU admission
News
FDA approves rivaroxaban for VTE prevention in hospitalized, acutely ill patients
October 15, 2019
The latest approval is based on results from the phase 3 MAGELLAN and MARINER trials, which included more than 20,000 patients.